Yasser Heakal, Ph.D.
|2009||Pennsylvania State University, State College, PA, United States|
Mean distance: 17811
ParentsSign in to add mentor
ChildrenSign in to add trainee
CollaboratorsSign in to add collaborator
BETA: Related publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.
|Heakal Y, Kester M, Savage S. (2011) Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma. The Annals of Pharmacotherapy. 45: 1399-405|
|Jiang Y, DiVittore NA, Kaiser JM, et al. (2011) Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer. Cancer Biology & Therapy. 12: 574-85|
|Heakal Y, Woll MP, Fox T, et al. (2011) Neurotensin receptor-1 inducible palmitoylation is required for efficient receptor-mediated mitogenic-signaling within structured membrane microdomains. Cancer Biology & Therapy. 12: 427-35|
|Heakal Y, Kester M. (2009) Nanoliposomal short-chain ceramide inhibits agonist-dependent translocation of neurotensin receptor 1 to structured membrane microdomains in breast cancer cells. Molecular Cancer Research : McR. 7: 724-34|
|Kester M, Heakal Y, Fox T, et al. (2008) Calcium phosphate nanocomposite particles for in vitro imaging and encapsulated chemotherapeutic drug delivery to cancer cells. Nano Letters. 8: 4116-21|
|Zolnik BS, Stern ST, Kaiser JM, et al. (2008) Rapid distribution of liposomal short-chain ceramide in vitro and in vivo. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 36: 1709-15|